Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors

US6921759B2 · kind B2 · utility

Assignee

• MERCK & CO., INC. · US

Inventors

• Neville J. Anthony · Hatfield, US
• Robert Gomez · Perkasie, US
• Steven D. Young · Lansdale, US
• Melissa Egbertson · Ambler, US
• John S. Wai · Harleysville, US
• Linghang Zhuang · Doylestown, US
• Mark W. Embrey · North Wales, US
• Jeffrey Melamed · North Wales, US
• H. Marie Langford · Marlboro, US
• James P. Guare, Jr. · Quakertown, US
• Thorsten E. Fisher · Hatfield, US
• Samson M. Jolly · Collegeville, US
• Michelle Kuo · Gwynedd Valley, US
• Debra S. Perlow · East Greenville, US
• Jennifer J. Bennett · Lansdale, US
• Timothy Funk · Ephrata, US

Key dates

• Filing date: Oct 10, 2001
• Grant date: Jul 26, 2005
• Expiry date: Feb 6, 2022

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P31/18
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Aza- and polyaza-naphthalenyl carboxamide derivatives including certain quinoline carboxamide and naphthyridine carboxamide derivatives are described. These compounds are inhibitors of HIV integrase and inhibitors of HIV replication, and are useful in the prevention or treatment of infection by HIV and the treatment of AIDS, as compounds or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of preventing, treating or delaying the onset of AIDS and methods of preventing or treating infection by HIV are also described.